Zepbound effective in obstructive sleep apnea trials
Eli Lilly’s obesity drug Zepbound has shown positive results in treating obstructive sleep apnea, positioning it as a potential first approved treatment for the disorder. In a year-long Phase 3 study, patients with obesity not on PAP therapy experienced a significant reduction in breathing interruptions during sleep while taking Zepbound compared to those on a…